75 results
Page 3 of 4
6-K
EX-99.1
fr26yr9 zajoxwe
21 Jan 21
Current report (foreign)
7:49am
6-K
EX-99.1
lkpo40
30 Nov 20
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial
5:10pm
6-K
EX-99.2
qrdav8xtj67 pvtx8w
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.1
1qo3u1orw71lpf6z
3 Nov 20
Current report (foreign)
6:00am
6-K
EX-99.1
6yw quwhsferante7cg
28 Sep 20
Current report (foreign)
6:00am
6-K
EX-99.2
831 u7dglgshy9k
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm
6-K
EX-99.1
lglak
26 May 20
Gilead and Galapagos Announce Positive Topline Results of Phase 2B/3 Trial of Filgotinib In Moderately to Severely Active Ulcerative Colitis
6:10am
6-K
EX-99.2
zjw20rv
11 May 20
Current report (foreign)
4:05pm
6-K
EX-99.1
i71z9xh
13 Jan 20
Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
6:06am
6-K
EX-99.1
nfs3to ek
20 Dec 19
Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment
6:01am
6-K
EX-99.2
8zmasgjq5u2h
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99
ion21v 2s
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm
6-K
EX-99.2
ksscuxul 99vm3h4
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
0kivh 7zhhxfm3
24 Apr 19
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
6:01am
6-K
EX-99.1
e5exw8 8rcvc8r
18 Dec 18
Current report (foreign)
6:07am
6-K
EX-99.1
iqess rkgz4opnvu
1 Nov 18
Current report (foreign)
10:06am
6-K
EX-99.2
ih12rmd15 i5
26 Oct 18
Hallmark third quarter 2018 and Annual R&D Update at Galapagos
4:19pm